Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2001-08-03
2004-01-20
Caputa, Anthony C. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C536S023400, C536S023500
Reexamination Certificate
active
06680371
ABSTRACT:
BACKGROUND OF THE INVENTION
Members of the Myc family of nuclear proto-oncogenes (c-, N- and L-Myc) play central roles in the control of normal growth and development and in genetic pathways linked to cellular transformation and apoptotic cell death. Accumulating structural, biochemical and genetic evidence affords the view that the function of Myc family oncoproteins in these diverse processes relates in part to their roles as sequence-specific transcription factors. Myc family proteins possess a multifunctional amino-terminal domain with transactivation potential, a region rich in basic amino acid residues responsible for sequence-specific DNA-binding activity, and a carboxy-terminal alpha-helical domain required for dimerization with another bHLH/LZ protein, Max. All known biological and biochemical activities of Myc are highly dependent upon its association with Max. In addition to its key role as an obligate partner in transactivation-competent Myc/Max complexes, Max can also repress Myc-responsive genes through the formation of transcriptional-repression complexes with members of the Mad family.
Several lines of evidence support the view that Mad and Mxi1 are important tumor suppressors. First, the addition of Mad or Mxi1 can dramatically reduce the oncogenic activity of Myc/Ras in the REF cooperation assay. Second, Nisen and coworkers (Chen, J., Willingham, T., Margraf, L. R., Schreiber-Agus, N., DePinho, R. A., and Nisen, P. D.,
Nature Medicine
1:638-643 (1995)) have shown that adenoviral constructs encoding Mad profoundly inhibit the proliferation and tumorigenicity of established human tumor cell lines. Third, Mad and Mxi1 map to cancer hotspots that are altered in a broad spectrum of different tumor types. Lastly, the preliminary assessment of Mxi1 knockout mice indicates that Mxi1-deficiency is associated with a cancer-prone condition.
From a mechanistic standpoint, the ability of Mad and Mxi1 to act as potent anti-Myc agents is dependent upon a short amino-terminal alpha-helical domain that allows for association with a mammalian protein that is structurally homologous to the yeast transcriptional repressor SIN3. The mechanistic basis for the mouse Sin3-mediated repression appears to be mediated in part through the recruitment of: (1) NcoR, a nuclear co-repressor that directly impacts on Pol II activity and (2) HD-1, a histone deacetylase that deacetylates histone H3 and H4 tails resulting in a condensed and less accessible nucleosomal arrangement. Structure-function studies of Sin3 indicate that its interaction with HD-1 is a critical requirement for Sin3-mediated anti-oncogenic activity in the context of Myc-induced cellular transformation.
Two domains known to be absolutely essential for Myc oncogenic activity have been mapped to the C-terminal bHLH/LZ structure and an amino-terminal segment designated Myc homology region II (MHRII). The inventors have recently cloned the drosophila homologue of Myc and have demonstrated that both of these signature features are conserved and, more strikingly, that drosophila Myc gene is oncogenic in mammalian cells. Over-expression of an MHRII fragment has been shown by others to inhibit the ability of Myc or E1a to cooperate with activated Ras in the REF assay. This finding, coupled with the formation of a specific complex between MHRII and a nuclear factor, suggests that MHRII oncogenic activity is dependent upon its ability to interact with an unidentified nuclear factor.
Myc has been shown to be directly involved in the genesis and progression of many different tumor types. Moreover, even when Myc deregulation is not the principal genetic lesion in human cancers, many cancer-associated lesions affect signaling pathways that feed into Myc and require Myc function in order to maintain the malignant phenotype.
Accordingly, there is a great need for the discovery of and characterization of proteins that interact with the MHRII of Myc. The isolation and characterization of proteins that interact with the MHRII of Myc allows for the design of agents that interact directly with MHRII to affect the regulation of Myc and ultimately target the actions of Myc. Targeting the actions of Myc oncoprotein can potentially have a significant impact on a very wide variety of human cancers, as well as many disorders arising from deregulated cellular growth or survival such as auto-immune disorders and psoriasis, among others.
SUMMARY OF THE INVENTION
The present invention provides for a novel purified Myc homology region II (MHRII)-associated protein, designated MHRII-AP62. Further provided by the present invention are antibodies immunoreactive with the MHRII-AP62 protein. Also provided are kits comprising MHRII-AP62 antibodies and methods of using the antibodies for the detection of the MHRII-AP62 protein and the diagnosis of cancers.
Further provided by the present invention is a nucleic acid sequence encoding the MHRII-AP62 protein, nucleic acid probes which hybridize to the nucleic acid sequence, and kits containing the probes for use in the diagnosis of cancers.
The present invention also provides a vector comprising a nucleic acid encoding a MHRII-AP62 protein, a cell stably transformed with this vector, as well as a method for producing recombinant MHRII-AP62 protein.
Also provided by the present invention are agents that mimic the activity of the MHRII-AP62 protein and bind to the binding domain of MHRII. Further provided are agents that inhibit the activity or expression of the MHRII-AP62 protein and inhibit the binding of the protein to MHRII, thus providing a means for assessing small molecule inhibitors to block or enhance MHRII-AP62 and MHRII interactions. Also provided are methods of treating cancer causing disease and reducing tumor growth using the agents.
Additional objects of the invention will be apparent from the description which follows.
REFERENCES:
patent: 6040425 (2000-03-01), DePinho
patent: 6297368 (2001-10-01), DePinho
DePinho, R. et al., Myc Family of Cellular Oncogenes, J. Cell Biochem., 33(4):257-66 (1987).
Schreiber-Agus, N et al., A biochemical and biological analysis of Myc superfamily interactions, Curr. Top. Microbiol. Immunol., vol. 224, pp. 159-168 (1997).
Alland, et al., Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression, Nature, 387 (6628): 49-55 (1997).
Schreiber-Agus, et al., Drosophila Myc is oncogenic in mammalian cells and plays a role in the diminutive phenotype, Proc. Natl. Acad. Sci. USA 94(4): 1235-40 (1997).
Chin et al., Contrasting roles for Myc and Mad proteins in cellular growth and differentiation, Proc. Natl. Acad. Sci. USA 92(18): 8488-92 (1995).
Chen, et al., Effects of the MYC oncogene antagonist, MAD, on proliferation, cell cycling and the malignant phentotype of human brain tumor cells, Nat. Med., 1(7): 638-43 (1995).
Chin, et al., Functional interactions among members of the Myc superfamily and potential relevance to cutaneous growth and development, J. Investig. Dermatol. Symp. Proc., 1(2): 128-35 (1996).
Mukherjee, et al., Myc family oncoproteins function through a common pathway to transform normal cells in culture: cross-interference by Max and trans-acting dominant mutants, Genes Dev., 6(8): 1480-92 (1992).
Torres, et al., Myc and Max: a putative transcriptional complex in search of a cellular target, Curr. Opin. Cell Biol., 4(3): 468-74 (1992).
FitzGerald, MJ, et al., 1999, Differential effects of the widely expressed dMax splice variant of Max on E-box vs initiator element-mediated regulation by c-Myc, Oncogene, vol. 18, pp. 2489-2498.
Schreiber-Agus, N., et al., 1998, Repression by the Mad(Mxil)-Sin3 complex, Bioessays, vol. 20, pp. 808-818.
Burgess et al., Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue. J Cell Biol vol. 111: 2129-2138, Nov. 1990.
Lazar et al., Transforming Growth Factor: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activiti
Albert Einstein College of Medicine of Yeshiva University
Amster Rothstein & Ebenstein LLP
Caputa Anthony C.
Rawlings Stephen L.
LandOfFree
Myc homology region II-associated protein and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Myc homology region II-associated protein and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Myc homology region II-associated protein and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3215994